Targets › HCRTR1
11 programs from 11 companies in 29 trials: 15 Phase 2, 8 Phase 4, 3 Phase 3, 3 Phase 1; Neurology, Psychiatry, Respiratory; next expected readout Dec 2026.
G protein-coupled receptor that binds the neuropeptide orexin-A with high affinity, and orexin-B with lower affinity, two peptides derived from a common precursor, prepro-orexin. Its activity is mediated via a G(q)-protein-coupled pathway, which activates the phosphatidylinositol-calcium second messenger system in response to orexin-A binding. (UniProt, O43613)
Open in Phaseline: the race on HCRTR1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | ALA 10% gel Muscle-type nicotinic acetylcholine receptor antagonist | HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1 | Phase 4 | Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder … | Dec 2026 |
| Stanford University | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 4 | Delayed Sleep Phase Syndrome | May 2027 |
| Mahidol University | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 4 | Sleep Disturbance | Dec 2027 |
| Nova Scotia Health Authority | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 4 | Insomnia | Dec 2028 |
| University of Manitoba | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 3 | Epilepsy | Apr 2027 |
| Merck & Co. (MSD) | Suvorexant (MK-4305) Orexin receptor antagonist | HCRTR2, HCRTR1 | Phase 3 | Insomnia; Alcohol Use Disorder (AUD); Suicide Risk; Autism … | Jun 2027 |
| Idorsia Pharmaceuticals | Daridorexant Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR2, HCRTR1 | Phase 3 | Insomia Disorder; Learning; Alzheimer Disease; Postoperative Cognitive Decline … | Nov 2027 |
| Flinders University | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 2 | OSA - Obstructive Sleep Apnea | May 2027 |
| Woolcock Institute of Medical Research | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 2 | Insomnia | Dec 2027 |
| Virginia Commonwealth University | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 2 | Opioid Use Disorder | Jul 2029 |
| University of Minnesota | Lemborexant Orexin receptor 1 antagonist; Orexin receptor 2 antagonist | HCRTR1, HCRTR2 | Phase 2 | Alzheimer Disease | Mar 2030 |
Insomnia (4) Alzheimer Disease (2) Insomia Disorder (1) Learning (1) Postoperative Cognitive Decline (1) Alzheimer Disease (AD) (1) Epilepsy (1) Delayed Sleep Phase Syndrome (1) Alcohol Use Disorder (AUD) (1) Suicide Risk (1) Autism (1) Sleep (1)
small molecule (11)
Idorsia Pharmaceuticals (1) University of Manitoba (1) Stanford University (1) Merck & Co. (MSD) (1) Virginia Commonwealth University (1) Flinders University (1) University of Minnesota (1) Mahidol University (1) Woolcock Institute of Medical Research (1) The University of Texas Health Science Center, Houston (1) Nova Scotia Health Authority (1)
HCRTR2 (11) CHRNA1 (1) CHRNG (1) CHRNB1 (1) CHRND (1) CHRNE (1) HTR2A (1) PTGS2 (1) PTGS1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.